Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026
Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026
Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026
Company Drug

Akeso Biopharma Initiates Phase II Global Study for Ligafulimab in High-Risk MDS

Fineline Cube Aug 5, 2024

China-based Akeso Biopharma (HKG: 9926) has reached a clinical milestone with the dosing of the...

Company

Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies

Fineline Cube Aug 5, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...

Policy / Regulatory

China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals

Fineline Cube Aug 2, 2024

The National Medical Products Administration (NMPA) of China has given the green light to Beijing...

Policy / Regulatory

China’s State Council Unveils Guidelines to Enhance Basic Medical Insurance System

Fineline Cube Aug 2, 2024

In a bid to address the evolving healthcare needs of an aging population and a...

Company Drug

AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal

Fineline Cube Aug 2, 2024

US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Mexico

Fineline Cube Aug 2, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in the medical device industry...

Company Drug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Fineline Cube Aug 2, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital

Fineline Cube Aug 2, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...

Company Deals

Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China

Fineline Cube Aug 2, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...

Company Drug

Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial

Fineline Cube Aug 2, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies

Fineline Cube Aug 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment

Fineline Cube Aug 2, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China

Fineline Cube Aug 2, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...

Company Drug

Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China

Fineline Cube Aug 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Drug

GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy

Fineline Cube Aug 2, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...

Company Deals

Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia

Fineline Cube Aug 2, 2024

China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...

Company Deals

Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus

Fineline Cube Aug 2, 2024

Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...

Company Deals

Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal

Fineline Cube Aug 2, 2024

Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...

Policy / Regulatory

US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry

Fineline Cube Aug 1, 2024

Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...

Policy / Regulatory

China’s Health Authorities Set Standards for Key Central Township Health Centers

Fineline Cube Aug 1, 2024

The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...

Posts pagination

1 … 367 368 369 … 713

Recent updates

  • Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
  • Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
  • HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
  • AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
  • Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.